What Is MOTS-c? Where It Came From, and When

What is MOTS-c, in one sentence: a short peptide encoded inside mitochondrial DNA rather than in the cell nucleus, studied mainly for effects on metabolism and insulin sensitivity, with a literature made up of cell and animal work and no human trial behind it at all. Everything else that gets said about it makes more sense once that origin is clear, so this page runs in the order the science did.

What is MOTS-c, stated in the order it was found

The unusual part comes first, because it explains the rest.

Almost every protein in a human cell is built from instructions in the nucleus. Mitochondria, the compartments that handle a cell's energy, carry their own small separate piece of DNA, a leftover of their origins. For a long time that piece was understood as coding for a short list of components used inside the mitochondrion itself, and nothing much else.

MOTS-c belongs to a group of peptides that complicated that picture. It is encoded within mitochondrial DNA, and it was identified as something produced from that genome that acts outside its own compartment, on the cell's wider metabolic signalling. That is the finding the compound is actually known for in biology, and it is a discovery about how cells work rather than a claim about a supplement.

The functional description attached to it in cell and rodent work involves metabolic signalling associated with the AMPK pathway, which cells use when energy is short. That is a description of a mechanism, meaning a route by which something might happen, not a report of an outcome in anybody.

How recent all of this actually is

The timeline is short, and its shortness is the single most useful fact about this compound.

The identification and characterisation work is recent by the standards of the compounds it is sold alongside. Several research chemicals in the same catalogue have literatures going back decades. This one does not, which means there has been less elapsed time for independent groups to reproduce findings, for contrary results to accumulate, and for the initial enthusiasm to be tested by people who were not involved at the start.

Next came the metabolic work in mice. Researchers created the metabolic conditions being studied, through diet or through a genetic trait, treated animals against a comparison group, and measured glucose handling and insulin sensitivity. That body of work in mice is where every metabolic claim about this peptide comes from.

Alongside that, an observation attracted a good deal of attention: levels of this peptide have been described as responsive to exercise, in mice and in human samples. That is a statement about physiology, and it cuts in an awkward direction for anyone selling the compound. Something the body produces more of when exercising is not automatically something that does more when supplied from outside.

Then the timeline stops. No human trial of this compound has been run, so the step that normally follows animal work has not been taken, and the last date in this sequence is a rodent one.

What sits where that step should be is a ClinicalTrials.gov record. NCT07505745 has every surface feature of the missing entry: a proper registry number, a Phase 2 label, a title about insulin sensitivity in adults with prediabetes and overweight or obesity, an enrolment figure of 120, and a status of recruiting. Its lead sponsor is Hudson Biotech, which holds seven further records first posted between February and April 2026, all recruiting, all naming the same single hospital, and between them covering BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide and TB-500. The TB-500 record, NCT07487363, opens its own brief summary by stating that it is a fictional study offered as an example of a ClinicalTrials.gov-style record.

The lesson generalises past this compound. Registration is not review. ClinicalTrials.gov accepts what is submitted rather than vetting it, so an NCT number establishes that somebody filed a form, and the fields that tell you whether to believe it are the lead sponsor and the brief summary, neither of which travels when a page cites the number alone.

Where it sits relative to the peptides it gets shelved beside

Sold in the same places as a dozen other compounds, it is easy to assume they are all in the same position. They are not, and the differences run both ways.

Compared with a peptide that has only cell data and marketing behind it, this one is further along, because someone with the resources to run a Phase 2 study in a defined clinical population decided the question was worth answering. That is a meaningful signal about how the metabolic evidence is regarded.

Compared with an approved medicine, it is nowhere near. An approved medicine has completed trials, published results, a regulator's review of the whole file, an agreed label, manufacturing standards enforced by inspection, and a system for collecting reports of harm afterwards. This compound has none of the six.

The comparison people most often make is to metabolic drugs used for glucose control, and that comparison is being made on the basis of a shared subject rather than a shared evidence base. Those drugs completed the sequence. This one has entered it.

Its regulatory position, stated plainly

No regulator anywhere has authorised this compound. Not the FDA, not the EMA, not the MHRA, and no other agency. It is not an approved medicine and it is not a licensed supplement.

What it is, commercially, is a research chemical. That designation matters more than most readers expect, because it defines what nobody is obliged to do. No one has to confirm that the vial contains what the label says. No one has to confirm the quantity, the purity, or that nothing else is present. No one has to confirm sterility. No one has to report harms, and no one is collecting them.

So there are two separate questions about anything bought this way, and they need separate answers. Does the molecule do something in people, which nothing currently under way is testing. And is the molecule in the vial, which no one has checked. A positive answer to the first would not change the second.

The wording on product listings is a consequence of all this. Phrases about laboratory use and not for human consumption are the legal position rather than a formality, and they are also an accurate description of where the evidence stands.

The three claims that do not belong to the biology

A page explaining what something is should also mark the places where the explanation gets extended past its source.

The first is ageing. This peptide came out of mitochondrial biology, and mitochondrial function is a subject that appears in ageing research, so the two get joined by proximity. There is no published human outcome connecting this compound to ageing in a person, and joining two topics is not evidence about either.

The second is energy, in the everyday sense of how someone feels at four in the afternoon. Mitochondria are described in every school textbook as the cell's energy producers, which makes the leap feel natural. Cellular energy metabolism and subjective tiredness are not the same variable, and no study in any organism has measured the second for this compound.

The third is athletic performance. This one borrows from the exercise observation described above, and it reverses its direction. Finding that exercise changes levels of something in mice and in human samples is not a finding that adding it improves performance, and no human trial has looked.

None of these three is disproven, and that word would be too strong. They are unsupported, meaning nothing was measured, which is a different and more basic problem than a study that came out badly.

What would move any of this forward

One thing, and it is specific. A human trial that genuinely exists, run by a sponsor who survives being looked up, reporting on insulin sensitivity in the population it enrolled.

That would produce the first measured human outcome for this compound. It would also be narrow, because such a study would enrol adults with prediabetes and overweight or obesity, and would speak to insulin sensitivity rather than to energy, ageing, athletic performance or body composition in healthy people. Claims about those would remain where they are now, which is attached to no measured endpoint in any organism.

Until then the accurate summary is two sentences long. The biology behind this peptide is genuine and interesting, and the animal work is focused rather than scattered. Nothing about its effects in people has been established, because no study that could establish it has ever been run, and there is no date on which that changes.